Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Published:2016-03 Issue:10023 Volume:387 Page:1075-1084
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Lublin Fred,Miller David H,Freedman Mark S,Cree Bruce A C,Wolinsky Jerry S,Weiner Howard,Lubetzki Catherine,Hartung Hans-Peter,Montalban Xavier,Uitdehaag Bernard M J,Merschhemke Martin,Li Bingbing,Putzki Norman,Liu Fonda C,Häring Dieter A,Kappos Ludwig

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Multiple sclerosis;Noseworthy;N Engl J Med,2000

2. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?;Antel;Acta Neuropathol,2012

3. The natural history of primary progressive multiple sclerosis;Koch;Neurology,2009

4. Defining the clinical course of multiple sclerosis: the 2013 revisions;Lublin;Neurology,2014

5. Pathological mechanisms in progressive multiple sclerosis;Mahad;Lancet Neurol,2015

Cited by 380 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-09-10

2. Assessing disease progression and treatment response in progressive multiple sclerosis;Nature Reviews Neurology;2024-09-09

3. Selecting informative patients for phase 2 progressive trials in MS: Design considerations for phase 2 clinical trials in progressive MS;Multiple Sclerosis Journal;2024-09-08

4. [Translated article] Risk of Skin Cancer Associated with Disease-Modifying Therapies in Multiple Sclerosis: A Comprehensive Evidence Review;Actas Dermo-Sifiliográficas;2024-09

5. Riesgo de cáncer cutáneo asociado a terapias modificadoras de la enfermedad en la esclerosis múltiple: revisión narrativa de la evidencia actual;Actas Dermo-Sifiliográficas;2024-09